

Radioactivity used in medicine, a land of opportunities

Nuclear medicine, proton therapy and brachytherapy are niche markets but growing more than twice as fast as the global health market

LOUVAIN-LA-NEUVE AND LALAYE,
BELGIUM AND FRANCE, January 27,
2016 /EINPresswire.com/ --
MEDraysintell offers the most
comprehensive set of reports and



directories, with over 1,800 pages of unrivaled intelligence covering some of the most exciting healthcare technologies using radiation for diagnosis and treatment.

[Nuclear medicine](#), [proton therapy](#) and [brachytherapy](#) are niche markets which together represents less than 0.1% of the global health expenditures but should grow more than twice as fast. While the global expenses on health reached some US\$ 7,400 billion in 2014 and should growth by 3-4% a year to 2030, the nuclear medicine, proton therapy and brachytherapy markets reached about US\$ 5.8 billion in 2014 and are expected to growth by 10-11% annually to 2030.

There is an increasing interest from investors and industry as new technologies and products are being marketed or under development.

The global nuclear medicine market is expected to reach US\$ 24 billion by 2030, showing an annual average growth of 11%, with radiotherapeutics being key drivers of this growth. The number of operational medical cyclotrons is also expected to grow with the emergence of the Asian and South American markets and the need of tools for new proprietary tracers.

The global proton therapy market saw record sales orders at just over US\$ 1 billion in 2015, more than twice as much as in 2014. There is now a clear positive stance on the future of the proton therapy market, and this technology is becoming a real part of the global radiotherapy world.

The global market for brachytherapy is expected to grow by 8% a year to 2030 mainly driven by the microspheres and electronic brachytherapy and with the LDR brachytherapy seeds market mainly growing in emerging regions.

MEDraysintell covers these markets in several reports and directories, which can be customized to specific areas or modalities. Sample pages and complete table of contents are available upon request. MEDraysintell also welcomes your requests for specific intelligence needs in these areas.

About MEDraysintell

Strategic intelligence for the radiation healthcare

Bringing value to Businesses and Investors!

MEDraysintell was founded in 2013 by Paul-Emmanuel Goethals (CSIntell) and Richard Zimmermann (Chrysalium Consulting). It combines over 40 years of experience in nuclear medicine, proton therapy and radiotherapy. We aim to form an international team of experts in the field of medical radiation to provide strategic intelligence in nuclear medicine, radiotherapy, proton therapy and brachytherapy to help our clients better understand the market – the competitive environment as well as the potential for mergers and acquisitions (M&A) – and technology development. MEDraysintell supports the decision process of manufacturers of radiopharmaceuticals and therapeutic radioisotopes, suppliers of equipment and software and members of the investor community. www.medraysintell.com

Paul-Emmanuel Goethals and Richard Zimmermann

MEDraysintell

+32 491 080 968 and +33 6 82 80 06 00

email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.